These little beans are nutrition powerhouses, packing protein, fiber, iron, manganese, folate, thiamin, potassium and other nutrients into a modest calorie count, with just a speck of fat and no cholesterol.
No new cholesterol drug has come close to generating the kind of mass-market use we saw with Lipitor and Zocor.
The U.S. patent on Pravachol expires in two years, and Bristol has no new cholesterol drugs likely to hit the market anytime soon.
Dr Heiner Berthold and colleagues tested commercial garlic oil preparations and found no evidence of lowered cholesterol levels.
They found the enriched eggs benefited both groups, with no negative effects on cholesterol concentrations, something UK dietary experts say is not a concern at that age anyway.
There's only one problem with this strategy: There is no proof that lowering cholesterol with a boost from Zetia is the same as using a more powerful statin.
One of the most prominent statisticians in the U.S. is taking issue with an analysis that claims there is no credible evidence the cholesterol drug Vytorin increases the risk of cancer death.
The only problem: So far there is no evidence that lowering cholesterol with Zetia is the same as it is when using one of the older drugs, which work in the liver.
Now doctors are left to ask when they will get more answers about a drug that has become widely used because it cut cholesterol, caused no obvious side effects and was heavily advertised.
For Merck and Schering-Plough, the pile-on over the cholesterol drug Vytorin shows no signs of letting up.
There is no evidence that really low LDL cholesterol levels are harmful.
Sir Richard Peto, the renowned British statistician who conducted an analysis showing "no credible evidence" that the cholesterol medicine Vytorin causes cancer, defended himself in a sharply worded letter to congressmen investigating the medicine.
According to a new report, about 71 million Americans in private insurance plans received expanded coverage of preventive services, such as mammograms and other cancer screenings, flu shots, and cholesterol checks, at no additional charge in 2011 and 2012.
The patients in the trial had already had a heart attack or other vascular disease severe enough to result in hospitalization, and the results may mean that when it comes to lowering cholesterol, there is no such thing as low enough.
Merck has lots of studies showing that Zetia lowers cholesterol, but there are no studies that show whether the drug prevents heart attacks.
Zetia is approved for lowering cholesterol, but there is no evidence it prevents heart attacks and saves lives like the statin drugs, including Lipitor and Zocor.
Doctors caution that no patient should just stop taking any cholesterol drug, because the life-saving benefits of the pills have been proven in large, well-designed studies.
Half of them also got Zetia, a second cholesterol drug, but there was no additional benefit on artery plaque.
But there is no such proof for Zetia, which lowers cholesterol but has not been shown to have other benefits.
There is no doubt that these medicines save lives--cholesterol pills such as Pfizer 's (nyse: PFE - news - people ) Lipitor and Merck 's (nyse: MRK - news - people ) Zocor have been shown to cut heart attacks by one-third.
Researchers at Cornell University tested the drug lovastatin, made by Merck Co. as Mevecor, on 6, 505 men and women who showed no signs of heart disease and had "average" cholesterol levels.
He points out that a study comparing a weak cholesterol drug to a powerful one would show no difference if only a few patients were studied, even if the powerful drug was in fact superior.
The inflammation theory helps explain why even someone with low cholesterol can have a heart attack, and why so many patients with no previous symptoms can suddenly be struck down.
Many low-carb or no-sugar products still contain large amounts of saturated fat, which can raise bad cholesterol and increase your risk of heart disease.
Those with good cholesterol levels typically don't have their hs-CRP levels tested because there are no clear guidelines on who should be tested and how often.
CNN: Study: Cholesterol drugs could help those with healthy levels
's expensive Vytorin had no benefit on the buildup of artery plaque over the older drug Zocor, even though Vytorin cut bad cholesterol 40% more.
Moreover, if TAK-475 is no more powerful than Zetia but has additional liver toxicity, its market will be limited to patients whose cholesterol is not lowered by the combination of a statin like Crestor and Zetia.
In a potentially damaging result, a long-delayed study showed Merck and Schering-Plough's expensive Vytorin had no benefit on the buildup of artery plaque over the older drug Zocor, even though Vytorin cut bad cholesterol 40% more.
应用推荐